Korean J Intern Med.
1997 Jan;12(1):52-57.
Serum and urine soluble HLA class I antigen concentrations are increased in
patients with hemorrhagic fever with renal syndrome
- Affiliations
-
- 1Department of Internal Medicine, Catholic University Medical College, Seoul,
Korea.
Abstract
OBJECTIVES
In order to evaluate the association between the Hantaan
virus-induced cellular-immune response and clinical severity in patients with
hemorrhagic fever with renal syndrome (HFRS). METHODS: We serially measured the
serum (n = 16) and urine (n = 6) concentrations of soluble HLA class 1 antigen
(sHLA-l) and clinical powameters in patients with HFRS. RESULTS: Serum sHLA-I
concentrations in patients with HFRS were significantly higher than those in
controls throughout all clinical phases (p < 0.01). The highly elevated Serum
sHLA-I concentrations peaked in the oliguric phase and declined gradually
through the phases of HFRS. Serum sHLA-l concentrations in patients with
hypotensive episode were higher than in those without the episode (5,85 +/-2,184
vs. 2,389 +/- 860 ng/ml in oliguric phase, 4.11 +/- 1,952 vs. 1,502 +/- 592
ng/ml in diuretic phase, p < 0.05), and serum sHLA-l levels showed a significant
correlation with blood WBC count (r = 0.75 in the febrile and hypotensive phase,
p < 0.01) and serum creatinine concentrations (r = 0.64 in the oliguric phase, p< 0.01), respectively, Urine sHLA-I levels in the oliguric phase were
significantly higher than those in the diuretic phase (390 +/- 155 vs. 214 +/-
45 ng/mg Cr, p < 0.05) and urine sHLA-I levels are associated with severe
illness in patients with HFRS. The higher serum sHLA-I are associated with
severe illness in patients with HFRS. The persistent elevation of serum sHLA-I
during all phases of HFRS might be related to increased production due to
prolonged cellular immunologic stimulation by the Hantaan virus rather than
decreased excretion of sHLA-I through the kidney. CONCLUSION: We suggest that
the serum and urine sHLA-I concentrations can be used as a stable and objective
parameter for monitoring clinical severity and renal dysfunction in patients
with HFRS.